DK1815853T3 - Terapeutisk middel (-)-(BPAP) mod stofafhængighed - Google Patents

Terapeutisk middel (-)-(BPAP) mod stofafhængighed

Info

Publication number
DK1815853T3
DK1815853T3 DK05809728T DK05809728T DK1815853T3 DK 1815853 T3 DK1815853 T3 DK 1815853T3 DK 05809728 T DK05809728 T DK 05809728T DK 05809728 T DK05809728 T DK 05809728T DK 1815853 T3 DK1815853 T3 DK 1815853T3
Authority
DK
Denmark
Prior art keywords
therapeutic agent
substance
substance dependence
bpap
craving
Prior art date
Application number
DK05809728T
Other languages
Danish (da)
English (en)
Inventor
Fumio Yoneda
Kazuhiko Morimoto
Tsuneyuki Yamamoto
Original Assignee
Univ Kyushu Nat Univ Corp
Fujimoto Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kyushu Nat Univ Corp, Fujimoto Co Ltd filed Critical Univ Kyushu Nat Univ Corp
Application granted granted Critical
Publication of DK1815853T3 publication Critical patent/DK1815853T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Addiction (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05809728T 2004-11-25 2005-11-21 Terapeutisk middel (-)-(BPAP) mod stofafhængighed DK1815853T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004339996A JP5030194B2 (ja) 2004-11-25 2004-11-25 薬物依存症治療剤
PCT/JP2005/021344 WO2006057211A1 (fr) 2004-11-25 2005-11-21 Agent therapeutique pour le traitement d'une dependance a une drogue

Publications (1)

Publication Number Publication Date
DK1815853T3 true DK1815853T3 (da) 2009-08-03

Family

ID=36497948

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05809728T DK1815853T3 (da) 2004-11-25 2005-11-21 Terapeutisk middel (-)-(BPAP) mod stofafhængighed

Country Status (15)

Country Link
US (2) US7825158B2 (fr)
EP (1) EP1815853B1 (fr)
JP (1) JP5030194B2 (fr)
KR (1) KR101096416B1 (fr)
CN (1) CN101065123B (fr)
AT (1) ATE429219T1 (fr)
AU (1) AU2005308258B2 (fr)
CA (1) CA2589289C (fr)
DE (1) DE602005014135D1 (fr)
DK (1) DK1815853T3 (fr)
ES (1) ES2325790T3 (fr)
HK (1) HK1113309A1 (fr)
IL (1) IL183028A (fr)
SI (1) SI1815853T1 (fr)
WO (1) WO2006057211A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100137429A1 (en) * 2007-06-21 2010-06-03 Fujimoto Co., Ltd. Composition for transdermal or transmucosal administration
BR112016014236A2 (pt) 2013-12-25 2017-08-08 Fujimoto Co Ltd Agente profilático e terapêutico para o distúrbio do déficit de atenção/hiperatividade
US10258598B2 (en) 2014-12-05 2019-04-16 Semmelweis University Compounds for use in the prevention or treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279114B2 (fr) 1986-11-21 1995-08-23 Glaxo Group Limited Médicaments pour le traitement ou la prévention du syndrome associé à un état de manque
DE3882712D1 (de) 1987-10-07 1993-09-02 Matrix Technologies Inc Pharmazeutische zusammensetzung fuer die behandlung der kokainsucht.
DE3930282A1 (de) 1989-09-11 1991-03-21 Boehringer Ingelheim Kg Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit
JP3601898B2 (ja) 1996-02-14 2004-12-15 俊隆 鍋島 薬物依存形成抑制剤
JPH1129476A (ja) 1997-05-16 1999-02-02 Grelan Pharmaceut Co Ltd 麻薬依存抑制剤
JP4499208B2 (ja) * 1998-10-29 2010-07-07 株式会社フジモト・コーポレーション 新規な光学活性アミノペンタン誘導体
JP4691230B2 (ja) * 2000-04-11 2011-06-01 株式会社フジモト・コーポレーション 光学活性1−(ベンゾフラン−2−イル)−2−プロピルアミノペンタンの製造方法
JP4953040B2 (ja) * 2001-09-19 2012-06-13 株式会社フジモト・コーポレーション アポトーシス抑制剤
JP4953041B2 (ja) * 2001-09-19 2012-06-13 株式会社フジモト・コーポレーション アポトーシス抑制剤

Also Published As

Publication number Publication date
AU2005308258A1 (en) 2006-06-01
ES2325790T3 (es) 2009-09-17
KR20070091610A (ko) 2007-09-11
JP5030194B2 (ja) 2012-09-19
CN101065123B (zh) 2012-02-15
CA2589289C (fr) 2013-04-30
IL183028A0 (en) 2007-10-31
JP2006151820A (ja) 2006-06-15
US8318799B2 (en) 2012-11-27
WO2006057211A1 (fr) 2006-06-01
CN101065123A (zh) 2007-10-31
IL183028A (en) 2011-12-29
AU2005308258B2 (en) 2011-02-24
SI1815853T1 (sl) 2009-10-31
EP1815853B1 (fr) 2009-04-22
ATE429219T1 (de) 2009-05-15
CA2589289A1 (fr) 2006-06-01
KR101096416B1 (ko) 2011-12-21
US7825158B2 (en) 2010-11-02
US20080004337A1 (en) 2008-01-03
DE602005014135D1 (de) 2009-06-04
US20100298426A1 (en) 2010-11-25
EP1815853A1 (fr) 2007-08-08
EP1815853A4 (fr) 2008-03-19
HK1113309A1 (en) 2008-10-03

Similar Documents

Publication Publication Date Title
ATE437184T1 (de) Varianten der fc-region
NL1028947A1 (nl) Gesubstitueerde methylaryl- of heteroarylamideverbindingen.
EA200601552A1 (ru) Замещенные конденсированные гетероциклические с-гликозиды
DE502006006854D1 (de) Substituierte benzo (d) isoaxol-3-yl-amin-verbindungen als analgetika
TW200700319A (en) Method for purifying hydrogen chloride
BRPI0607762B8 (pt) análogos de glp-1, composição farmacêutica contendo os mesmos e uso de um composto
EA200601555A1 (ru) Замещенные индазол-о-глюкозиды
NL1028948A1 (nl) Ortho gesubstitueerde aryl- of heteroarylamideverbindingen.
BR122012023120B8 (pt) Composto inibidor da recaptação de serotonina
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
TW200621937A (en) New compound and organic light emitting device using the same
CR10157A (es) Compuestos químicos
CY1112095T1 (el) Υποκατεστημενα σπειροκυκλικα παραγωγα κυκλοεξανιου
Guinchard et al. Total synthesis of marine sponge bis (indole) alkaloids of the topsentin class
CY1113320T1 (el) Σπειρο-κυκλικα νιτριλια ως αναστολεις πρωτεασης
CO5601045A2 (es) Procedimiento para la fabricacion de compuestos organicos
WO2007004092A3 (fr) Nouveaux intermediaires, processus destine a leur preparation et processus de preparation de coq10 utilisant lesdits nouveaux intermediaires
NO20085009L (no) Nye anvendelser av escitalopram
DK1815853T3 (da) Terapeutisk middel (-)-(BPAP) mod stofafhængighed
CY1110688T1 (el) Διεργασια για την παρασκευη καρβεδιλολης και εναντιομερων αυτης
TW200621843A (en) Solvent composition
WO2006080043A3 (fr) Composes organiques convenant pour le traitement de la maladie d'alzheimer, utilisation et methode de fabrication
ATE465153T1 (de) Neue indazolverbindungen mit kondensiertem ring
DE602004019698D1 (de) Morpholinderivate als inhibitoren der wiederaufnahme von norepinephrin
CY1108865T1 (el) Υποκατεστημενες 2,5-διαμινομευθυλο-1η-πυρρολες